Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dupilumab, a human monoclonal antibody against interleukin-4 receptor alpha, inhibits signaling of interleukin-4 and interleukin-13, type 2 cytokines that may be important drivers of atopic or allergic diseases such as atopic dermatitis. METHODS: In two randomized, placebo-controlled, phase 3 trials of identical design (SOLO 1 and SOLO 2), we enrolled adults with moderate-to-severe atopic dermatitis whose disease was inadequately controlled by topical treatment. Patients were randomly assigned in a 1:1:1 ratio to receive, for 16 weeks, subcutaneous dupilumab (300 mg) or placebo weekly or the same dose of dupilumab every other week alternating with placebo. The primary outcome was the proportion of patients who had both a score of 0 or 1 (clear or almost clear) on the Investigator's Global Assessment and a reduction of 2 points or more in that score from baseline at week 16. RESULTS: We enrolled 671 patients in SOLO 1 and 708 in SOLO 2. In SOLO 1, the primary outcome occurred in 85 patients (38%) who received dupilumab every other week and in 83 (37%) who received dupilumab weekly, as compared with 23 (10%) who received placebo (P<0.001 for both comparisons with placebo). The results were similar in SOLO 2, with the primary outcome occurring in 84 patients (36%) who received dupilumab every other week and in 87 (36%) who received dupilumab weekly, as compared with 20 (8%) who received placebo (P<0.001 for both comparisons). In addition, in the two trials, an improvement from baseline to week 16 of at least 75% on the Eczema Area and Severity Index was reported in significantly more patients who received each regimen of dupilumab than in patients who received placebo (P<0.001 for all comparisons). Dupilumab was also associated with improvement in other clinical end points, including reduction in pruritus and symptoms of anxiety or depression and improvement in quality of life. Injection-site reactions and conjunctivitis were more frequent in the dupilumab groups than in the placebo groups. CONCLUSIONS: In two phase 3 trials of identical design involving patients with atopic dermatitis, dupilumab improved the signs and symptoms of atopic dermatitis, including pruritus, symptoms of anxiety and depression, and quality of life, as compared with placebo. Trials of longer duration are needed to assess the long-term effectiveness and safety of dupilumab. (Funded by Sanofi and Regeneron Pharmaceuticals; SOLO 1 ClinicalTrials.gov number, NCT02277743 ; SOLO 2 ClinicalTrials.gov number, NCT02277769 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As neurons express receptors for IL-4 and IL-13, the early improvement of itch upon targeted therapy with dupilumab, tralokinumab or lebrikizumab supports the assumption of a direct effect of these drugs on nerve endings92,96,183.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [183]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Two phase 3 trials found dupilumab to significantly improve symptoms and quality of life in patients with AD compared to placebo [39].”
From Atopic dermatitis (2018) · cites this paper as [39]
The cited source says what the claim attributes to it.
In the citing paper
“Upadacitinib, a JAK inhibitor with proven efficacy in moderate-tosevere AD 30,31 , and dupilumab, an IL-4Rα antagonist that blocks IL-4/IL-13 signalling 32,33 , were selected.”
From Vascularized human skin assembloids model compartmental skin organization and immune responsiveness in vitro (2026) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139
The validity of the Hospital Anxiety and Depression Scale
Bjelland, I., Dahl, A. A., Haug, T. T., & Neckelmann, D. (2002) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(01)00296-3 · Cited by 9,779
Severity Scoring of Atopic Dermatitis: The SCORAD Index
(2009) · Dermatology · doi:10.1159/000247298 · Cited by 2,273
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
Beck, L. A., Thaçi, D., Hamilton, J. D., Graham, N. M., Bieber, T., Rocklin, R., Ming, J. E., Ren, H., Kao, R., Simpson, E., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314768 · Cited by 1,421
Self-citationDupilumab in Persistent Asthma with Elevated Eosinophil Levels
Wenzel, S., Ford, L., Pearlman, D., Spector, S., Sher, L., Skobieranda, F., Wang, L., Kirkesseli, S., Rocklin, R., Bock, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304048 · Cited by 1,320
Self-citationGuidelines of care for the management of atopic dermatitis
Eichenfield, L. F., Tom, W. L., Berger, T. G., Krol, A., Paller, A. S., Schwarzenberger, K., Bergman, J. N., Chamlin, S. L., Cohen, D. E., Cooper, K. D., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.023 · Cited by 1,224
Self-citationThe eczema area and severity index (EASI): assessment of reliability in atopic dermatitis
Hanifin, J. M., Thurston, M., Omoto, M., Cherill, R., Tofte, S. J., Graeber, M., & Evaluator Group, T. E. (2001) · Experimental Dermatology · doi:10.1034/j.1600-0625.2001.100102.x · Cited by 1,200
Atopic dermatitis: a disease of altered skin barrier and immune dysregulation
Boguniewicz, M., & Leung, D. Y. M. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01027.x · Cited by 1,073
Wenzel, S., Castro, M., Corren, J., Maspero, J., Wang, L., Zhang, B., Pirozzi, G., Sutherland, E. R., Evans, R. R., Joish, V. N., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30307-5 · Cited by 985
Self-citationGittler, J. K., Shemer, A., Suárez-Fariñas, M., Fuentes-Duculan, J., Gulewicz, K. J., Wang, C. Q. F., Mitsui, H., Cardinale, I., de Guzman Strong, C., Krueger, J. G., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.07.012 · Cited by 981
Self-citation
Cited by
Items 301–400 of 1,002
Glaubitz, J., Asgarbeik, S., Lange, R., Mazloum, H., Elsheikh, H., Weiß, F. U., & Sendler, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1279539 · Cited by 97
“Dupilumab, an IL-4/IL-13 receptor blocking antibody, is used in dermatitis as well as asthma (120, 121).”
BackgroundFrom Emollients to Biologicals: Targeting Atopic Dermatitis
Salvati, L., Cosmi, L., & Annunziato, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910381 · Cited by 93
Dupilumab ocular side effects in patients with atopic dermatitis: a systematic review
Neagu, N., Dianzani, C., Avallone, G., Dell’Aquila, C., Morariu, S. ‐., Zalaudek, I., & Conforti, C. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17981 · Cited by 84
Current and emerging concepts in atopic dermatitis pathogenesis
Sullivan, M., & Silverberg, N. B. (2017) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2017.03.006 · Cited by 84
Dupilumab (Dupixent): An Interleukin-4 Receptor Antagonist for Atopic Dermatitis.
D'Ippolito, D., & Pisano, M. (2018) · Europe PMC (PubMed Central) · Cited by 76
Ferastraoaru, D. E., Bax, H. J., Bergmann, C., Capron, M., Castells, M., Dombrowicz, D., Fiebiger, E., Gould, H. J., Hartmann, K., Jappe, U., et al. (2020) · Clinical and Translational Allergy · doi:10.1186/s13601-020-00335-w · Cited by 90
Prevalence, pathophysiology and management of itch in epidermolysis bullosa*
Papanikolaou, M., Onoufriadis, A., Mellerio, J. E., Nattkemper, L. A., Yosipovitch, G., Steinhoff, M. S., & McGrath, J. A. (2020) · British Journal of Dermatology · doi:10.1111/bjd.19496 · Cited by 83
Corren, J., Saini, S. S., Gagnon, R., Moss, M. H., Sussman, G. L., Jacobs, J., Laws, E., Chung, E. S., Constant, T., Sun, Y., et al. (2021) · Journal of Asthma and Allergy · doi:10.2147/jaa.s318892 · Cited by 80
T‐cell subsets in the skin and their role in inflammatory skin disorders
Krohn, I. K., Aerts, J. L., Breckpot, K., Goyvaerts, C., Knol, E. F., van Wijk, F., & Gutermuth, J. (2021) · Allergy · doi:10.1111/all.15104 · Cited by 93
Raffi, J., Suresh, R., Botto, N., & Murase, J. E. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.09.028 · Cited by 76
Cicatricial ectropion in a patient treated with dupilumab
Barnes, A. C., Blandford, A. D., & Perry, J. D. (2017) · American Journal of Ophthalmology Case Reports · doi:10.1016/j.ajoc.2017.06.017 · Cited by 78
Pulmonary group 2 innate lymphoid cells: surprises and challenges
Starkey, M. R., McKenzie, A. N. J., Belz, G. T., & Hansbro, P. M. (2019) · Mucosal Immunology · doi:10.1038/s41385-018-0130-4 · Cited by 86
Chiricozzi, A., Maurelli, M., Gori, N., Argenziano, G., SIMONE, C. D., Calabrese, G., Girolomoni, G., & Peris, K. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.03.049 · Cited by 78
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult Subjects
Li, Z., Radin, A. R., Li, M., Hamilton, J. D., Kajiwara, M., Davis, J. D., Takahashi, Y., Hasegawa, S., Ming, J. E., DiCioccio, A. T., et al. (2020) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.798 · Cited by 80
Self-citationZhao, Y. P., Wu, L., Lu, Q., Gao, X., Zhu, X., Yao, X., Li, L., Li, W., Ding, Y., Song, Z., et al. (2021) · British Journal of Dermatology · doi:10.1111/bjd.20690 · Cited by 77
Mashiah, J., Karady, T., Isakov, N. F., Sprecher, E., Slodownik, D., Artzi, O., Samuelov, L., Ellenbogen, E., Godneva, A., Segal, E., et al. (2021) · Immunity Inflammation and Disease · doi:10.1002/iid3.570 · Cited by 81
Dupilumab in Adults With Moderate to Severe Atopic Dermatitis: A 5-Year Open-Label Extension Study
Beck, L. A., Bissonnette, R., Deleuran, M. S., Nakahara, T., Galus, R., Coleman, A., Gherardi, G., Xiao, J., Dingman, R. K., Xu, C. R., et al. (2024) · JAMA Dermatology · doi:10.1001/jamadermatol.2024.1536 · Cited by 85
Self-citationNahum, Y., Mimouni, M., Livny, E., Bahar, I., Hodak, E., & Leshem, Y. A. (2019) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2019-315010 · Cited by 76
Atopic dermatitis guidelines: Diagnosis, systemic therapy, and adjunctive care
Sidbury, R., & Kodama, S. (2018) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2018.05.008 · Cited by 85
Staphylococcus aureus second immunoglobulin-binding protein drives atopic dermatitis via IL-33
Al Kindi, A., Williams, H., Matsuda, K., Alkahtani, A. M., Saville, C., Bennett, H., Alshammari, Y., Tan, S. Y., O’Neill, C., Tanaka, A., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.09.023 · Cited by 73
Girolomoni, G., Luger, T. A., Nosbaum, A., Gruben, D. C., Romero, W., Llamado, L. J. Q., & DiBonaventura, M. (2020) · Dermatology and Therapy · doi:10.1007/s13555-020-00459-8 · Cited by 82
Atopic dermatitis: Pathophysiology, microbiota, and metabolome – A comprehensive review
Mohammad, S., Karim, M. R., Iqbal, S., Lee, J. H., Mathiyalagan, R., Kim, Y. J., Yang, D. U., & Yang, D. (2024) · Microbiological Research · doi:10.1016/j.micres.2023.127595 · Cited by 93
Maspero, J. F., Katelaris, C. H., Busse, W. W., Castro, M., Corren, J., Chipps, B. E., Peters, A. T., Pavord, I. D., Ford, L. B., Sher, L., et al. (2019) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2019.07.016 · Cited by 74
Self-citationWhich Way Do We Go? Complex Interactions in Atopic Dermatitis Pathogenesis
Patrick, G. J., Archer, N. K., & Miller, L. S. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.07.006 · Cited by 85
“In phase III trials, AD patients treated with dupilumab achieved 36–38% improvement in the primary endpoint of the investigator global assessment (IGA) (compared with 8–10% of the placebo group) and nearly 50% of AD patients treated with dupilumab achieved at least 75% on the Eczema Area and Severity Index (EASI-75) (…”
BackgroundThyssen, J. P., de Bruin‐Weller, M. S., Paller, A. S., Leshem, Y. A., Vestergaard, C., Deleuran, M., Drucker, A. M., Foelster‐Holst, R., Traidl‐Hoffmann, C., Eyerich, K., et al. (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15608 · Cited by 71
Self-citationSkin-Resident Innate Lymphoid Cells – Cutaneous Innate Guardians and Regulators
Kobayashi, T., Ricardo-Gonzalez, R. R., & Moro, K. (2020) · Trends in Immunology · doi:10.1016/j.it.2019.12.004 · Cited by 71
“The promising clinical efficacy of monoclonal antibodies blocking IL-4 and IL-13 signaling in patients with atopic dermatitis has definitively demonstrated a predominant role for type 2 cytokines in the pathogenesis of atopic dermatitis [50,51].”
BackgroundGenetics of eosinophilic esophagitis
Kottyan, L. C., & Rothenberg, M. E. (2017) · Mucosal Immunology · doi:10.1038/mi.2017.4 · Cited by 82
Erythrodermic presentation of psoriasis in a patient treated with dupilumab
Tracey, E. H., Elston, C. A., Feasel, P. C., Piliang, M. P., Michael, M., & Vij, A. (2018) · JAAD Case Reports · doi:10.1016/j.jdcr.2018.05.014 · Cited by 71
“Entry into clinical trials of dupilumab are very closely controlled, with inclusion criteria mandating diagnostic rigor, specific disease severity scores and areas of body surface involvement, and inadequate response to prior treatments.(4) Based on”
Pathophysiology of Atopic Dermatitis and Psoriasis: Implications for Management in Children
Chovatiya, R., & Silverberg, J. I. (2019) · Children · doi:10.3390/children6100108 · Cited by 87
Self-citationNovel Strategies to Target Mast Cells in Disease
Paivandy, A., & Pejler, G. (2021) · Journal of Innate Immunity · doi:10.1159/000513582 · Cited by 80
Interleukin-4 as a therapeutic target
Gärtner, Y., Bitar, L., Zipp, F., & Vogelaar, C. F. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108348 · Cited by 76
Eye Complications During Dupilumab Treatment for Severe Atopic Dermatitis
Ivert, L. U., Wahlgren, C., Ivert, L. U., Lundqvist, M., & Bradley, M. (2019) · Acta Dermato Venereologica · doi:10.2340/00015555-3121 · Cited by 69
Mümmler, C., Munker, D., Barnikel, M., Veit, T., Kayser, M. Z., Welte, T., Behr, J., Kneidinger, N., Suhling, H., & Milger, K. (2020) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2020.09.014 · Cited by 74
Group 2 Innate Lymphoid Cells: Team Players in Regulating Asthma
Rodríguez‐Rodríguez, N., Gogoi, M., & McKenzie, A. N. J. (2021) · Annual Review of Immunology · doi:10.1146/annurev-immunol-110119-091711 · Cited by 76
Possible roles of basophils in chronic itch
Hashimoto, T., Rosen, J. D., Sanders, K. M., & Yosipovitch, G. (2018) · Experimental Dermatology · doi:10.1111/exd.13705 · Cited by 74
Development of inflammatory arthritis and enthesitis in patients on dupilumab: a case series
Willsmore, Z. N., Woolf, R., Hughes, C., Menon, B. S., Kirkham, B. W., Smith, C. H., & Pink, A. (2019) · British Journal of Dermatology · doi:10.1111/bjd.18031 · Cited by 69
New and developing therapies for atopic dermatitis
Hajar, T., Gontijo, J. R. V., & Hanifin, J. M. (2018) · Anais Brasileiros de Dermatologia · doi:10.1590/abd1806-4841.20187682 · Cited by 68
Current Use of Probiotics and Prebiotics in Allergy
Fiocchi, A. G., Cabana, M. D., & Mennini, M. (2022) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2022.06.038 · Cited by 80
Sensory neuronal STAT3 is critical for IL-31 receptor expression and inflammatory itch
Takahashi, S., Ochiai, S., Jin, J., Takahashi, N., Toshima, S., Ishigame, H., Kabashima, K., Kubo, M., Nakayama, M., Shiroguchi, K., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113433 · Cited by 73
Emerging Treatment Options in Atopic Dermatitis: Systemic Therapies
Nygaard, U., Vestergaard, C., & Deleuran, M. S. (2017) · Dermatology · doi:10.1159/000484406 · Cited by 74
Self-citationEmerging Role of the IL-36/IL-36R Axis in Multiple Inflammatory Skin Diseases
Ahmad, F., Alam, M. A., Ansari, A. W., Jochebeth, A., Leo, R., Al-Abdulla, M. N., Al‐Khawaga, S., AlHammadi, A., Al-Malki, A., Naama, K. A., et al. (2024) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2023.11.004 · Cited by 72
Weidinger, S., Blauvelt, A., Papp, K. A., Reich, A., Lee, C., Worm, M., Lynde, C. W., Kataoka, Y., Foley, P. A., Wei, X., et al. (2024) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2024.10.031 · Cited by 69
Self-citationRavn, N. H., Ahmadzay, Z. F., Christensen, T. A., Larsen, H. H. P., Loft, N., Rævdal, P., Heegaard, S., Kolko, M., Egeberg, A., Silverberg, J. I., et al. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.11.037 · Cited by 70
Self-citationCutaneous T‐cell lymphoma following dupilumab use: a systematic review
Park, A., Wong, L., Lang, A., Kraus, C. N., Anderson, N., & Elsensohn, A. N. (2022) · International Journal of Dermatology · doi:10.1111/ijd.16388 · Cited by 71
Chronic Pruritus: Current and Emerging Treatment Options
Pereira, M. P., & Ständer, S. (2017) · Drugs · doi:10.1007/s40265-017-0746-9 · Cited by 72
“Dupilumab, an anti-interleukin (IL)-4/-13 antibody, which is administered subcutaneously once a week, significantly reduced pruritus and disease activity in patients with atopic dermatitis resistant to conventional therapies [45, 46] and is soon expected to be the first biologic approved for atopic dermatitis.”
BackgroundDupilumab use in allergic contact dermatitis
Machler, B. C., Sung, C. T., Darwin, E., & Jacob, S. E. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.07.043 · Cited by 68
Role of Type 2 Innate Lymphoid Cells in Allergic Diseases
Cosmi, L., Liotta, F., Maggi, L., & Annunziato, F. (2017) · Current Allergy and Asthma Reports · doi:10.1007/s11882-017-0735-9 · Cited by 73
Nettis, E., Ferrucci, S. M., Ortoncelli, M., Pellacani, G., Foti, C., Leo, E. D., Patruno, C., Rongioletti, F., Argenziano, G., Macchia, L., et al. (2020) · Journal of Investigational Allergology and Clinical Immunology · doi:10.18176/jiaci.0641 · Cited by 69
“For our cohort of patients, the eosinophil count did not change significantly between baseline and week 16 of follow-up, in line with previously reported data from clinical trials [9-11].”
BackgroundResultInfluentialZhang, Y., Yan, B., Shen, S., Song, X., Jiang, Y., Shi, L., Zhao, C., Yang, Y., Jiang, L., Li, J., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102076 · Cited by 69
Izuhara, K., Yamaguchi, Y., Ohta, S., Nunomura, S., Nanri, Y., Azuma, Y., Nomura, N., Noguchi, Y., & Aihara, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041102 · Cited by 67
“Recently, dupilumab, an antagonist against the IL-4 receptor α chain (IL-4Rα) important for the signals of both IL-4 and IL-13, signature cytokines of type 2 inflammation, has been launched as the first molecularly targeted drug for treating AD patients [69].”
BackgroundCohen, J. N., Bowman, S., Laszik, Z. G., & North, J. P. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.08.023 · Cited by 65
Applications of Human Skin Microbiota in the Cutaneous Disorders for Ecology-Based Therapy
Zhou, H. W., Shi, L., Ren, Y., Tan, X., Liu, W., & Liu, Z. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.570261 · Cited by 68
Zhao, Y. P., Zhang, L., Ding, Y., Tao, X., Ji, C., Dong, X., Lu, J., Wu, L., Wang, R., Lu, Q., et al. (2021) · American Journal of Clinical Dermatology · doi:10.1007/s40257-021-00627-2 · Cited by 65
“The interleukin (IL)-4 receptor inhibitor dupilumab was recently approved in several countries for the treatment of moderate to severe AD; while this introduction brings a new treatment option, there remain opportunities for improvements in efficacy in terms of eczema severity and onset of pruritus relief [20, 21].”
BackgroundOral Janus kinase inhibitors for atopic dermatitis
Mikhaylov, D., Ungar, B., Renert‐Yuval, Y., & Guttman‐Yassky, E. (2023) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2023.01.020 · Cited by 70
Self-citationButala, S., Castelo‐Soccio, L. A., Seshadri, R., Simpson, E. L., O’Shea, J. J., Bieber, T. R. M., & Paller, A. S. (2023) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2023.03.011 · Cited by 71
Self-citationSilverberg, J. I., Bunick, C. G., Hong, H., Mendes‐Bastos, P., Gold, L. S., Costanzo, A., Ibrahim, N., Sancho, C., Wu, X., Han, Y. J., et al. (2024) · British Journal of Dermatology · doi:10.1093/bjd/ljae404 · Cited by 86
Self-citationTsianakas, A., Luger, T. A., & Radin, A. R. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15905 · Cited by 66
Molecular and Cellular Approaches to the Treatment of Neurological Disease
Lam, R. W. M. (1993) · Journal of Psychiatry and Neuroscience · Cited by 64
Atopic Dermatitis: Collegium Internationale Allergologicum (CIA) Update 2019
Simon, D., Wollenberg, A., Renz, H. E., & Simon, H. (2019) · International Archives of Allergy and Immunology · doi:10.1159/000497383 · Cited by 75
Self-citationIgelman, S., Kurta, A. O., Sheikh, U. A., McWilliams, A., Armbrecht, E. S., Jackson, S. R., Kress, D. W., Smith, A. P., Castelo‐Soccio, L. A., Treat, J. R., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.10.010 · Cited by 63
English Version of Clinical Practice Guidelines for the Management of Atopic Dermatitis 2021
Saeki, H., Ohya, Y., Furuta, J., Arakawa, H., Ichiyama, S., Katsunuma, T., Katoh, N., Tanaka, A., Tsunemi, Y., Nakahara, T., et al. (2022) · The Journal of Dermatology · doi:10.1111/1346-8138.16527 · Cited by 75
Executive summary: Japanese guidelines for atopic dermatitis (ADGL) 2021
Saeki, H., Ohya, Y., Furuta, J., Arakawa, H., Ichiyama, S., Katsunuma, T., Katoh, N., Tanaka, A., Tsunemi, Y., Nakahara, T., et al. (2022) · Allergology International · doi:10.1016/j.alit.2022.06.009 · Cited by 69
Clark, R. A., & Schlapbach, C. (2016) · Seminars in Immunopathology · doi:10.1007/s00281-016-0607-8 · Cited by 71
The use of biologics for immune modulation in allergic disease
van de Veen, W., & Akdiş, M. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124607 · Cited by 67
Heratizadeh, A., Haufe, E., Stölzl, D., Abraham, S., Heinrich, L., Kleinheinz, A., Wollenberg, A., Weißhaar, E., Augustin, M., Wiemers, F., et al. (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16078 · Cited by 68
Self-citationAgache, I. O., Song, Y., Posso, M., Alonso‐Coello, P., Rocha, C., Solà, I., Beltran, J., Akdiş, C. A., Akdiş, M., Brockow, K., et al. (2020) · Allergy · doi:10.1111/all.14510 · Cited by 67
Self-citationHan, Y., Chen, Y., Liu, X., Zhang, J., Su, H., Wen, H., Li, W., & Yao, X. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.04.015 · Cited by 65
“…q2w for 16 weeks 38.0(27.5-48.0)/39.0 (27.0-50.5) ‡ 300mg qw:30.4(21.5-40.8), 300mg q2w:29.8(22.0-41.2) /31.8(22.2-43.8) ‡ clinical index improvement in dupilumab group Simpson et al,2016 2016 SOL O2 III Multina tional NCT0227776 9 472/236 300mg qw for 16 weeks,300mg q2w for…”
InfluentialBiological therapies for atopic dermatitis: An update�(Review)
Deleanu, D., & Nedelea, I. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6989 · Cited by 62
“control groups investigated the efficacy and safety of Dupilumab in AD (50-57).”
Health Utility Scores of Atopic Dermatitis in US Adults
Silverberg, J. I., Gelfand, J. M., Margolis, D. J., Boguniewicz, M., Fonacier, L. S., Grayson, M. H., Ong, P. Y., Fuxench, Z. C. C., & Simpson, E. L. (2018) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2018.11.043 · Cited by 67
Self-citationSilverberg, J. I., Simpson, E. L., Ardeleanu, M., Thaçi, D., Barbarot, S., Bagel, J., Chen, Z., Eckert, L., Chao, J., Korotzer, A. R., et al. (2019) · British Journal of Dermatology · doi:10.1111/bjd.17791 · Cited by 65
Self-citationSkin‐infiltrating basophils promote atopic dermatitis‐like inflammation via IL‐4 production in mice
Yamanishi, Y., Mogi, K., Takahashi, K., Miyake, K., Yoshikawa, S., & Karasuyama, H. (2020) · Allergy · doi:10.1111/all.14362 · Cited by 62
Frew, J. W., Jiang, C. S., Singh, N., Grand, D., Navrazhina, K., VAUGHAN, R. D., & Krueger, J. G. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.12.044 · Cited by 64
Knobler, R., Arenberger, P., Arun, A., Assaf, C., Bagot, M., Berlin, G., Bohbot, A., Calzavara‐Pinton, P., Child, F. J., Cho, A., et al. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16889 · Cited by 67
Systemic treatments for eczema: a network meta-analysis
Sawangjit, R., Dilokthornsakul, P., Lloyd-Lavery, A., Lai, N. M., Dellavalle, R. P., & Chaiyakunapruk, N. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013206.pub2 · Cited by 80
Clinical phenotypes of adult atopic dermatitis and related therapies
Patruno, C., Potestio, L., & Napolitano, M. (2022) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000837 · Cited by 63
Molina, B., Padoan, R., Urban, M. L., Novikov, P. I., Caminati, M., Taillé, C., Néel, A., Bouillet, L., Fraticelli, P., SCHLEINITZ, N., et al. (2023) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2023-224756 · Cited by 71
Ohanyan, T., Schoepke, N., Eirefelt, S., Hoey, G., Koopmann, W., Hawro, T., Maurer, M., & Metz, M. (2017) · Acta Dermato Venereologica · doi:10.2340/00015555-2780 · Cited by 63
Therapeutic Targeting of the Interleukin-4/Interleukin-13 Signaling Pathway: In Allergy and Beyond
Karo‐Atar, D., Bitton, A., Benhar, I., & Munitz, A. (2018) · BioDrugs · doi:10.1007/s40259-018-0280-7 · Cited by 67
“Common adverse events in the dupilumab-treated patients were injection-site reactions and conjunctivitis [99].”
BackgroundA Clinician’s Guide to the Recognition and Management of Dupilumab-Associated Conjunctivitis
Agnihotri, G., Shi, K., & Lio, P. (2019) · Drugs in R&D · doi:10.1007/s40268-019-00288-x · Cited by 66
“The pathogenesis of conjunctivitis in dupilumab-treated patients is not well-understood, but several theories have been postulated: reduction in ocular cytokines provides a favorable environment for Demodex mites to grow, causing IL-17-mediated inflammation [19]; eosinophilia after dupilumab administration [12]; incre…”
BackgroundImmunosensation: Neuroimmune Cross Talk in the Skin
Tamari, M., Heul, A. V., & Kim, B. (2021) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101719-113805 · Cited by 64
Spekhorst, L. S., Bakker, D. S., Drylewicz, J., Rispens, T., Loeff, F. C., Boesjes, C. M., Thijs, J. L., Romeijn, G. L. E., Loman, L., Schuttelaar, M. L. A., et al. (2022) · Allergy · doi:10.1111/all.15439 · Cited by 68
What’s New in Atopic Dermatitis
Renert-Yuval, Y., & Guttman-Yassky, E. (2019) · Dermatologic Clinics · doi:10.1016/j.det.2018.12.007 · Cited by 60
Self-citationMiake, S., Tsuji, G., Takemura, M., Hashimoto‐Hachiya, A., Vu, Y. H., Furue, M., & Nakahara, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20164053 · Cited by 61
“It has been shown that the anti-IL-4 receptor alpha (IL-4RA) antibody dupilumab causes marked and rapid improvement in AD patients [6], indicating that IL-4 plays a critical role in AD development.”
BackgroundKallikrein 7 Promotes Atopic Dermatitis-Associated Itch Independently of Skin Inflammation
Guo, C. J., Mack, M. R., Oetjen, L. K., Trier, A. M., Council, M. L., Pavel, A. B., Guttman-Yassky, E., Kim, B. S., & Liu, Q. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2019.10.022 · Cited by 59
“Additionally, clinical trials with dupilumab, an anti-IL-4Ra monoclonal antibody, have demonstrated rapid and marked improvement of itch symptoms in patients with AD (Beck et al., 2014; Guttman-Yassky et al., 2019; Simpson et al., 2016; Thaçi et al., 2016).”
BackgroundSelf-citationReal-world persistence with dupilumab among adults with atopic dermatitis
Silverberg, J. I., Guttman‐Yassky, E., Gadkari, A. S., Kuznik, A., Mallya, U. G., Mastey, V., Zhang, H., Chen, Z., Chen, C., Korotzer, A. R., et al. (2020) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2020.07.026 · Cited by 60
Self-citationDupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic Dermatitis
Boguniewicz, M., Beck, L. A., Sher, L., Guttman‐Yassky, E., Thaçi, D., Blauvelt, A., Worm, M., Corren, J., Soong, W., Lio, P., et al. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2020.12.059 · Cited by 61
Self-citationOxidative Stress and Phototherapy in Atopic Dermatitis: Mechanisms, Role, and Future Perspectives
Borgia, F., Pomi, F. L., Vaccaro, M., Alessandrello, C., Papa, V., & Gangemi, S. (2022) · Biomolecules · doi:10.3390/biom12121904 · Cited by 71
“Dupilumab, the first biological drug approved by the FDA for moderate-to-severe AD, binds to the IL-4Ra, inhibiting IL-4 and IL-13 signaling, and has demonstrated an improvement of at least 75% on the Eczema Area and Severity Index (EASI), on pruritus, and QoL as compared to placebo [39].”
BackgroundKim, R. W., Lam, M., Abuabara, K., Simpson, E. L., & Drucker, A. M. (2024) · American Journal of Clinical Dermatology · doi:10.1007/s40257-023-00837-w · Cited by 72
“Compared with placebo, dupilumab has shown to improve or clear atopic dermatitis and associated symptoms as well as improve quality of life in both 16 and 52 week phase 3 clinical trials [23–27].”
Self-citationPaller, A. S., Siegfried, E. C., Simpson, E. L., Cork, M. J., Sidbury, R., Chen, I. H., Khokhar, F. A., Xiao, J., Dubost-Brama, A., & Bansal, A. (2024) · American Journal of Clinical Dermatology · doi:10.1007/s40257-024-00859-y · Cited by 77
“Similarly, in previous controlled studies in adults, adolescents, and older children, incidence of skin infection TEAEs was lower in the dupilumab arm compared with the placebo arm [32–36].”
ResultSelf-citationThe Antipruritic Effect of Phototherapy
Legat, F. J. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00333 · Cited by 66
“As aforementioned, the importance of IL-4 and IL-13 in AD was highlighted by the newly developed and already licensed antibody dupilumab, which targets the IL-4-receptor alpha-chain of the heterodimeric IL-4 and IL-13 receptors, and, thus, blocks both IL-4 and IL-13 mediated effects, which has shown significant antipr…”
BackgroundAchten, R., Bakker, D. S., Ariëns, L. F. M., Lans, A., Thijs, J. L., van der Schaft, J., de Boer, J. H., Balak, D., de Graaf, M., van Luijk, C., et al. (2020) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2020.09.042 · Cited by 58
Husein‐ElAhmed, H., & Steinhoff, M. S. (2020) · Journal of Dermatological Treatment · doi:10.1080/09546634.2020.1853024 · Cited by 62
Janus kinase inhibitors for atopic dermatitis: a promising treatment modality
Cartron, A. M., Nguyen, T., Roh, Y. S., Kwatra, M. M., & Kwatra, S. G. (2021) · Clinical and Experimental Dermatology · doi:10.1111/ced.14567 · Cited by 58
Rogers, L., Jeseňák, M., Bjermer, L., Hanania, N., Seys, S., & Diamant, Z. (2023) · Respiratory Medicine · doi:10.1016/j.rmed.2023.107414 · Cited by 57
The Psychology of Atopic Dermatitis
Courtney, A., & Su, J. C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061602 · Cited by 83
“It can severely impact sleep, schooling, work, and family relationships; visible disfigurement from redness, flaking, and bleeding excoriations can result in social stigmatisation, withdrawal, and reduced QOL [2,3].”
BackgroundEffective use of dupilumab in managing systemic allergic contact dermatitis
Joshi, S. R., & Khan, D. A. (2018) · Dermatitis® · doi:10.1097/der.0000000000000409 · Cited by 58
Silverberg, J. I. (2018) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2018.09.029 · Cited by 65
Self-citationInnate Lymphoid Cells of the Lung
Barlow, J. L., & McKenzie, A. N. J. (2019) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020518-114630 · Cited by 63
Bosma, A. L., de Wijs, L. E. M., Hof, M. H. P., van Nieuwenhuizen, B. R., Gerbens, L. A. A., Middelkamp-Hup, M. A., Hijnen, D., & Spuls, P. I. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.05.128 · Cited by 60
“Conjunctivitis has been a commonly reported AE in clinical trials.(18,19,25) Daily practice literature has shown incidences of conjunctivitis ranging from 8.”
BackgroundMustafa, S. S., Vadamalai, K., Scott, B., & Ramsey, A. C. (2020) · American Journal of Rhinology and Allergy · doi:10.1177/1945892420961969 · Cited by 63
Metadata
- Authors
- Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., Kingo, K., Worm, M., Poulin, Y., Wollenberg, A., Soo, Y., Graham, N. M. H., Pirozzi, G., Akinlade, B., Staudinger, H., Mastey, V., Eckert, L., Gadkari, A., Stahl, N., Yancopoulos, G. D., & Ardeleanu, M.
- Affiliations
- University of Bonn (DE)
- Northwestern University (US)
- ORCID
- Simpson, Eric L.
- Bieber, Thomas
- Beck, Lisa A.
- Blauvelt, Andrew
- Cork, Michael J.
- Silverberg, Jonathan I.
- Deleuran, Mette
- Kataoka, Yoko
- Lacour, Jean-Philippe
- Kingo, Külli
- Worm, Margitta
- Poulin, Yves
- Wollenberg, Andreas
- Soo, Yuhwen
- Graham, Neil M.H.
- Pirozzi, Gianluca
- Akinlade, Bolanle
- Staudinger, Heribert
- Eckert, Laurent
- Stahl, Neil
- Ardeleanu, Marius
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-12-15
- Volume
- 375
- Issue
- 24
- Pages
- 2335-2348
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2524051065
- Cited by
- 2,110
- References
- 38
- Citations by year
- 2026: 183 · 2025: 219 · 2024: 227 · 2023: 239 · 2022: 218 · 2021: 238 · 2020: 244 · 2019: 236 · 2018: 160 · 2017: 130 · 2016: 8
- FWCI
- 211.58
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion, other-oa)
- Scopus (Elsevier) (submittedVersion)
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Keywords
- ab, atopic dermatitis, IL-4 receptor alpha, IL-13, IL-4, type 2 cytokines, monoclonal antibodies, subcutaneous administration, dosing frequency, Investigator's Global Assessment, Eczema Area and Severity Index, pruritus, injection site reactions, conjunctivitis, quality of life
- MeSH terms
- Adult, Anti-Inflammatory Agents, Antibodies, Monoclonal, Dermatitis, Atopic, Double-Blind Method, Female, Humans, Injections, Subcutaneous, Male, Middle Aged, Nasopharyngitis, Pruritus, Quality of Life, Interleukin-4, Interleukin-13, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.